ATN Profile

CPT: 83520(x4)
Print Share


  • Alzheimer's
  • Amyloid-Tau-Neurodegeneration (ATN) Profile
  • Beta Amyloid 42/40 Ratio, Plasma
  • Neurofilament Light Chain(NfL), Plasma
  • Phosphorylated Tau 181 (pTau-181), Plasma

Test Includes

Beta Amyloid 42/40 Ratio; Phosphorylated Tau 181 (pTau-181); Neurofilament Light Chain (NfL)

Special Instructions

This test currently is not available in New York state.

Expected Turnaround Time

7 - 10 days

Related Documents

For more information, please view the literature below.

What is the importance of ATN in Alzheimer's disease?

Specimen Requirements


Plasma, frozen


3 mL

Minimum Volume

2.5 mL (Note: This volume does not allow for repeat testing.)


Lavender-top (EDTA) tube, screw-capped frozen transport tube


Draw two full lavender-top (EDTA) tubes of blood. Separate plasma from blood via centrifugation (>1500g for 10 minutes) within 40 minutes after blood collection. Transfer plasma to two Labcorp polypropylene transport tubes and seal.

Storage Instructions

Plasma samples may be stored for up to 24 hours at < -10°C (standard freezer) prior to placing in dry ice (for shipment), or samples may be stored in the refrigerator for up to 10 hours but then must be placed on dry ice for transport. All samples must be placed on dry ice for transport and must be maintained on dry ice or similar temperatures when reaching the local lab.

Stability Requirements



Room temperature

4 hours


10 hours


-10°C: 24 hours; < -60°C: 100 days

Freeze/thaw cycle

Stable x1

Causes for Rejection

Sample at room temperature; thawed sample; only one tube of plasma

Test Details


This profile is used to assist in determining the presence or absence of key biological changes that are consistent with Alzheimer's disease pathology.


These tests were developed and their performance characteristics determined by Labcorp. They have not been cleared or approved by the Food and Drug Administration.


Sysmex chemiluminescence enzyme immunoassay (CLEIA) and Roche Diagnostics electrochemiluminescence immunoassay (ECLIA)

Additional Information

The ATN framework provides an objective approach to determine the status of biological changes that are indicative of Alzheimer’s disease (AD). Overall, the ATN framework for blood-based biomarkers can complement imaging and CSF analysis and create an opportunity for a more effective patient journey. The ATN Profile test employs biomarkers that have been well-studied in clinical research:

A: Plasma Aβ42/40 immunoassay based on Sysmex reagents and technology. In general, Aβ42 proteins are known to have a high adhesion index and are typically referred to as “sticky,” thus complicating their assessment in blood or CSF samples. New technologies—including low binding tubes and high sensitivity immunoassay platforms that can detect down to picogram levels—have enabled better assessments. Ovod et al demonstrated that accurate amyloid beta assessments for AD from blood were possible using mass spectrometry techniques.1 More recently, studies using Sysmex-based technology showed that plasma Aβ42/40 assessments could achieve levels similar to mass spectrometry-based methods for detecting AD pathology.2,3

T: Plasma pTau-181 immunoassay based on Roche reagents and technology. Karikari et al showed the diagnostic utility of plasma pTau-181 in AD4 and additional studies that same year demonstrated that plasma pTau-181 correlates with tau PET,5,6 thereby validating it as an important and useful BBM for AD pathology determination. Subsequent studies have demonstrated the prognostic value of combining Aβ42/40 testing with plasma pTau-181 on a Roche platform.7

N: Plasma NfL immunoassay based on Roche reagents and technology. NfL is an indicator of neurodegeneration but is not specific to any particular disease, as neurofilaments in blood are simply the result of axonal damage, regardless of cause. In CSF, total Tau is a key biomarker for neurodegeneration. However, for a complete blood-based solution, NfL is the more suitable biomarker8 for determining neurodegenerative disease staging.9,10 The new updated draft guidelines do demote NfL from a core biomarker to a secondary one. Labcorp has chosen to leave the marker in the profile for clinical purposes since, even in the setting of normal beta-amyloid results, a raised NfL result may help alert the clinician to another non-Alzheimer’s condition.


1. Ovod V, Ramsey KN, Mawuenyega KG, et al. Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement. 2017 Aug;13(8):841-849.28734653
2. Yamashita K, Miura M, Watanabe S, et al. Fully automated and highly specific plasma β-amyloid immunoassays predict β-amyloid status defined by amyloid positron emission tomography with high accuracy. Alzheimers Res Ther. 2022 Jun 23;14(1):86.35739591
3. Yamashita K, Watanabe S, Ishiki K, et al. Fully automated chemiluminescence enzyme immunoassays showing high correlation with immunoprecipitation mass spectrometry assays for β-amyloid (1-40) and (1-42) in plasma samples. Biochem Biophys Res Commun. 2021 Oct 22;576:22-26.34478915
4. Karikari TK, Pascoal TA, Ashton NJ, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020 May;19(5):422-433.32333900
5. Thijssen EH, La Joie R, Wolf A, et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration. Nat Med. 2020 Mar;26(3):387-397.32123386
6. Janelidze S, Mattsson N, Palmqvist S, et al. Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia. Nat Med. 2020 Mar;26(3):379-386.32123385
7. Palmqvist S, Stomrud E, Cullen N, et al. An accurate fully automated panel of plasma biomarkers for Alzheimer's disease. Alzheimers Dement. 2023 Apr;19(4):1204-1215.35950735
8. Janelidze S, Palmqvist S, Leuzy A, et al. Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p-tau. Alzheimers Dement. 2022 Feb;18(2):283-293.34151519
9. Ebenau JL, Pelkmans W, Verberk IMW, et al. Association of CSF, plasma, and imaging markers of neurodegeneration with clinical progression in people with subjective cognitive decline. Neurology. 2022 Mar 29;98(13):e1315-e1326.35110378
10. Iaccarino L, Burnham SC, Dell'Agnello G, Dowsett SA, Epelbaum S. Diagnostic Biomarkers of Amyloid and Tau Pathology in Alzheimer's Disease: An Overview of Tests for Clinical Practice in the United States and Europe. J Prev Alzheimers Dis. 2023;10(3):426-442.37357283


Order Code Order Code Name Order Loinc Result Code Result Code Name UofM Result LOINC
484400 ATN Profile 484403 A -- Beta-amyloid 42/40 Ratio Pending
484400 ATN Profile 484406 Beta-amyloid 42 pg/mL 33200-7
484400 ATN Profile 484408 Beta-amyloid 40 pg/mL 70073-2
484400 ATN Profile 484404 T -- p-tau181 pg/mL Pending
484400 ATN Profile 484405 N -- NfL, Plasma pg/mL 101281-4
484400 ATN Profile 484119 ATN SUMMARY[1] N/A
484400 ATN Profile 484407 Information: N/A
Reflex Table for ATN SUMMARY[1]
Order Code Order Name Result Code Result Name UofM Result LOINC
Reflex 1 484401 ATN SUMMARY[1] 484401 ATN SUMMARY[1] Pending

For Providers

Please login to order a test

Order a Test

© 2023 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.

CPT Statement/Profile Statement

The LOINC® codes are copyright © 1994-2023, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at Additional information regarding LOINC® codes can be found at, including the LOINC Manual, which can be downloaded at